Reglan Adverse Events More Than Doubled from 2006 to 2008


Recent data from the Food and Drug Administration’s Adverse Event

Reporting System reveals that new cases of tardive dyskinesia or other movement disorders reported by users of Reglan (or its generic version, metoclopramide) more than doubled between 2006 and 2008, according to an analysis by Hissey Kientz, LLP. This represents a substantial increase in new adverse events related to Reglan.

LOADING PDF: If there are any problems, click here to download the file.